Skip to main content

AbbVie Inc. (ABBV)

NYSE: ABBV · IEX Real-Time Price · USD
109.14 0.38 (0.35%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap192.87B
Revenue (ttm)53.73B
Net Income (ttm)6.66B
Shares Out1.77B
EPS (ttm)3.71
PE Ratio29.43
Forward PE7.89
Dividend$5.08 (4.65%)
Ex-Dividend DateOct 14, 2021
Volume4,614,352
Open108.67
Previous Close108.76
Day's Range108.31 - 109.21
52-Week Range75.49 - 120.07
Beta0.83
AnalystsBuy
Price Target127.01 (+16.4%)
Est. Earnings DateOct 29, 2021

About ABBV

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, mar...

IndustryBiotechnology
CEORichard Gonzalez
Employees48,000
Stock ExchangeNYSE
Ticker SymbolABBV
Full Company Profile

Financial Performance

In 2020, AbbVie's revenue was $45.80 billion, an increase of 37.69% compared to the previous year's $33.27 billion. Earnings were $4.62 billion, a decrease of -41.44%.

Financial Statements

Analyst Forecast

According to 22 analysts, the average rating for AbbVie stock is "Buy." The 12-month stock price forecast is 127.01, which is an increase of 16.37% from the latest price.

Price Target
$127.01
(16.37% upside)
Analyst Consensus: Buy

News

AbbVie (ABBV) Earnings Expected to Grow: Should You Buy?

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

15 hours ago - Zacks Investment Research

7 A-Rated Dividend Stocks to Buy for Q4

These are among the best dividend stocks to buy for Q4. Each has an A-rating in Dividend Grader, including OMC stock and SNA stock.

Other symbols:AFLALLCINFIPGOMCSNA
2 days ago - InvestorPlace

Could This Beaten-Down Biotech Stock Be the Next Buyout Target?

This gene-therapy specialist may need some help turning things around.

Other symbols:AZNBLUEBMY
3 days ago - The Motley Fool

3 Biopharma Stocks To Watch Following Johnson & Johnson's Earnings Beat

Johnson & Johnson (NYSE:JNJ) shares are higher Tuesday following the release of its third-quarter results. J&J A Bellwether For The Sector: Given the timing of J&J's earnings release and its portfolio b...

Other symbols:JNJAMGNLLY
3 days ago - Benzinga

3 Leading Healthcare Stocks to Buy in 2021 and Beyond

Three healthcare stocks that have momentum on their side and are good buys right now.

Other symbols:RMDWBA
4 days ago - The Motley Fool

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

AbbVie (ABBV) closed the most recent trading day at $107.43, moving -1.74% from the previous trading session.

4 days ago - Zacks Investment Research

7 Blue Chips to Shield Your Portfolio From Market Downturn

Blue-chip stocks that have growing cash flow, good value, and have strong growth are suitable investments as the market downturn worsens. The post 7 Blue Chips to Shield Your Portfolio From Market Downt...

Other symbols:EDKOPEPPGRTXUL
5 days ago - InvestorPlace

3 High-Yield Dividend Stocks I'm Not Selling Anytime Soon

I'm not yielding with these great dividend stocks.

Other symbols:DVNEPD
5 days ago - The Motley Fool

3 Best Dividend Stocks for Retirement

These companies have positioned themselves to provide a generous and rising income stream.

Other symbols:STORVZ
6 days ago - The Motley Fool

2 Buffett Stocks to Buy and Hold Forever

The Oracle of Omaha is largely a set-and-forget kind of investor and you should be, too.

Other symbols:AMZN
1 week ago - The Motley Fool

AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic A...

NORTH CHICAGO, Ill., Oct. 15, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approva...

1 week ago - PRNewsWire

Want More Monthly Income? Invest in These 3 Stocks

They all pay more than double what you'll get with the average stock in the S&P 500.

Other symbols:BCEENB
1 week ago - The Motley Fool

3 Small Biotech Stocks in Focus on World Arthritis Day

Here we discuss three drugs or biotech companies with promising candidates in their pipeline for Arthritis indications.

Other symbols:ALPNAMGNBVSIMABJNJ
1 week ago - Zacks Investment Research

AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

In the latest trading session, AbbVie (ABBV) closed at $110.34, marking a -0.76% move from the previous day.

1 week ago - Zacks Investment Research

This is Why AbbVie (ABBV) is a Great Dividend Stock

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?

1 week ago - Zacks Investment Research

Allergan Aesthetics Launches Series of Initiatives to Support Breast Cancer Awareness

IRVINE, Calif., Oct. 11, 2021 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is continuing its commitment to breast health, awareness, restoration, and research in support of breas...

1 week ago - PRNewsWire

AbbVie Touts Additional Rinvoq Data In Inflammatory Spinal Arthritis

AbbVie Inc (NYSE: ABBV) has churned out new data for Rinvoq in the hope that adding more evidence will back the JAK inhibitor's megablockbuster potential. Related:   AbbVie Submits Upadacitinib Applicat...

2 weeks ago - Benzinga

Why AbbVie Stock Sank in September

A regulatory setback weighed on the drugmaker's shares last month.

2 weeks ago - The Motley Fool

AbbVie's Upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic...

NORTH CHICAGO, Ill., Oct. 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from Study 2 of the Phase 3 SELECT-AXIS 2 clinical trial in adults with active non-radiogr...

2 weeks ago - PRNewsWire

AbbVie's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondyl...

NORTH CHICAGO, Ill., Oct. 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from the first of two studies of the Phase 3 SELECT-AXIS 2 clinical trial evaluating the e...

2 weeks ago - PRNewsWire

9 Big Pharmaceutical Stocks Sporting Stellar Yields

Large-cap pharmaceutical stocks offer investors stable, substantial dividends, regardless of market conditions. Here are nine that stand out.

2 weeks ago - Kiplinger

AbbVie to Host Third-Quarter 2021 Earnings Conference Call

NORTH CHICAGO, Ill., Oct. 5, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2021 financial results on Friday, October 29, 2021, before the market opens.

2 weeks ago - PRNewsWire

AbbVie (ABBV) Stock Moves -0.33%: What You Should Know

AbbVie (ABBV) closed the most recent trading day at $108.73, moving -0.33% from the previous trading session.

2 weeks ago - Zacks Investment Research

AbbVie to Showcase New Data at the United European Gastroenterology (UEG) Week Virtual 2021

NORTH CHICAGO, Ill., Oct. 2, 2021 /PRNewswire/ -- AbbVie today announced new data on the investigational use of risankizumab (SKYRIZI®) in Crohn's disease, upadacitinib (RINVOQ®) in ulcerative colitis a...

2 weeks ago - PRNewsWire

Here's What Warren Buffett Looks For With Healthcare Stocks

There's a reason why there are so few of them in his portfolio.

Other symbols:BIIBISRGRVP
3 weeks ago - The Motley Fool